ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients in a few years' time.
company data |
|
| employees: | 21 - 50 |
| legal form: | Gesellschaft mit beschränkter Haftung |
| commercial register number: | FN397151x |
| founding date: | 2013 |
| member of cluster: | |
export countries: |
|
| global | |
products and services: |
|
| Innovative virus-based therapeutics for cancer treatment | |
research and innovation |
|
| Development of innovative virus-based therapeutics for cancer treatment | |
contact information |
|
| street: | Bundesstraße 27 |
| ZIP code: | 6063 |
| city: | Rum |
| country: | Österreich |
| phone: | +43 512 272 061 |
| email: | office@viratherapeutics.com |
| website: | http://www.viratherapeutics.com |
|
contact: |
Dr. Lisa Egerer |
| function: | |
| phone: | +43 512 272 061 72 |
| email: | egerer@viratherapeutics.com |
-
competences and specialization
- pharmaceutical products
- pre clinical development
- remedies based on biological materials